Posted in

No Scarcity of Wegovy Weight-Loss Drug in Denmark, Novo Nordisk Says

No Shortage of Wegovy Weight Loss Drug in Denmark Novo Nordisk Says


COPENHAGEN (Reuters) – Novo Nordisk doesn’t anticipate a scarcity of its Wegovy weight-loss drug in Denmark regardless of an earlier warning by the Danish Medicines Company of strained provide of two separate doses within the coming weeks, the corporate mentioned.

The Danish regulator on Monday issued two statements saying the nation confronted a scarcity of the Wegovy Flextouch 1 mg injection pen from late Could to mid-June and the 0.5 mg Wegovy Flextouch injection pen between mid-June and mid-July.

In each circumstances, the anticipated scarcity was as a result of rising demand, the medicines company mentioned.

“Novo Nordisk is experiencing a excessive demand for Wegovy, which can lead to periodic backorders of assorted doses of the product in Denmark,” Novo Nordisk mentioned in a press release to Reuters late on Tuesday.

“Within the case of Wegovy FlexTouch 1.0 mg and 0.5 mg, the bulletins from the Danish Medicines Company are not present,” it mentioned.

Wegovy is given by weekly injection and belongs to a category of medicine referred to as GLP-1 agonists initially developed to deal with kind 2 diabetes.

Weekly Wegovy injections begin at 0.25 mg of energetic ingredient semaglutide and progressively improve to the upkeep dose of two.4 mg.

Novo, which has been battling provide constraints as a result of run-away demand for the vastly fashionable drug mentioned all doses had been accessible in Denmark.

(Reporting by Louise Rasmussen and Stine Jacobsen, modifying by Terje Solsvik)

Copyright 2024 Thomson Reuters.

Photographs You Ought to See – Could 2024

Protesters carry balloons to a march on International Workers' Day in Santiago, Chile, Wednesday, May 1, 2024. (AP Photo/Matias Basualdo)

Leave a Reply

Your email address will not be published. Required fields are marked *